Ioannis Pozios1, Nina N Seel2, Nina A Hering1, Lisa Hartmann1, Verena Liu1,3, Peter Camaj2,4, Mario H Müller1,3, Lucas D Lee1, Christiane J Bruns4, Martin E Kreis1, Hendrik Seeliger5. 1. Department of General, Visceral and Vascular Surgery, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. 2. Department of General, Visceral and Transplantation Surgery, Hospital of the University of Munich, Munich, Germany. 3. Department of Minimal Invasive and Visceral Surgery, Vivantes Klinikum Neukölln, Berlin, Germany. 4. Department of General, Visceral, Cancer and Transplant Surgery, University Hospital of Cologne, Cologne, Germany. 5. Department of General, Visceral and Vascular Surgery, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. hendrik.seeliger@charite.de.
Abstract
PURPOSE: Currently, the exact role of estrogen receptor (ER) signaling in pancreatic cancer is unknown. Recently, we showed that expression of phosphorylated ERβ correlates with a poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here, we hypothesized that raloxifene, a FDA-approved selective ER modulator (SERM), may suppress PDAC tumor growth by interfering with ERβ signaling. To test this hypothesis, we studied the impact of raloxifene on interleukin-6/glycoprotein-130/signal transducer and activator of transcription-3 (IL-6/gp130/STAT3) signaling. METHODS: Human PDAC cell lines were exposed to raloxifene after which growth inhibition was assessed using a BrdU assay. ER knockdown was performed using siRNAs specific for ERα and ERβ. The effects of raloxifene on IL-6 expression and STAT3 phosphorylation in PDAC cells were assessed by ELISA and Western blotting, respectively. In addition, raloxifene was administered to an orthotopic PDAC tumor xenograft mouse model, after which tumor growth was monitored and immunohistochemistry was performed. RESULTS: Raloxifene inhibited the in vitro growth of PDAC cells, and this effect was reversed by siRNA-mediated knockdown of ERβ, but not of ERα, indicating ER isotype-specific signaling. We also found that treatment with raloxifene inhibited the release of IL-6 and suppressed the phosphorylation of STAT3Y705 in PDAC cells. In vivo, we found that orthotopic PDAC tumor growth, lymph node and liver metastases as well as Ki-67 expression were reduced in mice treated with raloxifene. CONCLUSIONS: Inhibition of ERβ and the IL-6/gp130/STAT3 signaling pathway by raloxifene leads to potent reduction of PDAC growth in vitro and in vivo. Our results suggest that ERβ signaling and IL-6/gp130 interaction may serve as promising drug targets for pancreatic cancer and that raloxifene may serve as an attractive therapeutic option for PDAC patients expressing the ERβ isotype.
PURPOSE: Currently, the exact role of estrogen receptor (ER) signaling in pancreatic cancer is unknown. Recently, we showed that expression of phosphorylated ERβ correlates with a poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here, we hypothesized that raloxifene, a FDA-approved selective ER modulator (SERM), may suppress PDACtumor growth by interfering with ERβ signaling. To test this hypothesis, we studied the impact of raloxifene on interleukin-6/glycoprotein-130/signal transducer and activator of transcription-3 (IL-6/gp130/STAT3) signaling. METHODS:HumanPDAC cell lines were exposed to raloxifene after which growth inhibition was assessed using a BrdU assay. ER knockdown was performed using siRNAs specific for ERα and ERβ. The effects of raloxifene on IL-6 expression and STAT3 phosphorylation in PDAC cells were assessed by ELISA and Western blotting, respectively. In addition, raloxifene was administered to an orthotopic PDACtumor xenograft mouse model, after which tumor growth was monitored and immunohistochemistry was performed. RESULTS:Raloxifene inhibited the in vitro growth of PDAC cells, and this effect was reversed by siRNA-mediated knockdown of ERβ, but not of ERα, indicating ER isotype-specific signaling. We also found that treatment with raloxifene inhibited the release of IL-6 and suppressed the phosphorylation of STAT3Y705 in PDAC cells. In vivo, we found that orthotopic PDACtumor growth, lymph node and liver metastases as well as Ki-67 expression were reduced in mice treated with raloxifene. CONCLUSIONS: Inhibition of ERβ and the IL-6/gp130/STAT3 signaling pathway by raloxifene leads to potent reduction of PDAC growth in vitro and in vivo. Our results suggest that ERβ signaling and IL-6/gp130 interaction may serve as promising drug targets for pancreatic cancer and that raloxifene may serve as an attractive therapeutic option for PDACpatients expressing the ERβ isotype.
Authors: S Tomao; A Romiti; B Massidda; M T Ionta; A Farris; A Zullo; A Brescia; L Santuari; L Frati Journal: Anticancer Res Date: 2002 Jul-Aug Impact factor: 2.480
Authors: Usama A Fahmy; Shaimaa M Badr-Eldin; Hibah M Aldawsari; Nabil A Alhakamy; Osama A A Ahmed; Mohamed F Radwan; Basma G Eid; Shaban R M Sayed; Gamal A El Sherbiny; Walaa Abualsunun Journal: Drug Deliv Date: 2022-12 Impact factor: 6.819
Authors: Lucas D Lee; Ioannis Pozios; Verena Liu; Silke B Nachbichler; Dirk Böhmer; Carsten Kamphues; Katharina Beyer; Christiane J Bruns; Martin E Kreis; Hendrik Seeliger Journal: Radiat Environ Biophys Date: 2022-01-27 Impact factor: 2.017
Authors: Nikita Abramenko; Fréderic Vellieux; Petra Tesařová; Zdeněk Kejík; Robert Kaplánek; Lukáš Lacina; Barbora Dvořánková; Daniel Rösel; Jan Brábek; Adam Tesař; Milan Jakubek; Karel Smetana Journal: Int J Mol Sci Date: 2021-06-18 Impact factor: 5.923